GEVA

Synageva BioPharma Corp. Press Releases

$91.28
*  
1.56
1.74%
Get GEVA Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading GEVA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA
12/23/2014 11:26:00 AM - PR Newswire


Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA
12/23/2014 11:26:00 AM - PR Newswire
▼-0.58 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST
12/17/2014 8:00:00 AM - PR Newswire
▲4.46 % Price Change since this news event. The Volume Ratio is 1.35.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB
12/15/2014 7:00:00 AM - PR Newswire
▼-0.02 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa And Submits Marketing Authorization Application To European Medicines Agency
12/2/2014 9:02:00 AM - PR Newswire
▲15.62 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting
11/10/2014 1:42:00 PM - PR Newswire
▲20.37 % Price Change since this news event. The Volume Ratio is 1.26.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Reports Third Quarter 2014 Financial Results
10/30/2014 4:05:00 PM - PR Newswire
▲14.01 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma to Present at the Nomura Biotechnology Conference
10/29/2014 7:05:00 AM - PR Newswire
▲16.59 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting
10/23/2014 4:05:00 PM - PR Newswire
▲19.96 % Price Change since this news event. The Volume Ratio is 0.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa
10/21/2014 4:05:00 PM - PR Newswire
▲24.80 % Price Change since this news event. The Volume Ratio is 0.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


WiLAN Subsidiary Enters Agreement With RPX
10/8/2014 10:30:00 AM - Market Wire


Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral Presentation During The Late-Breaking Session At The Liver Meeting®
10/8/2014 10:04:00 AM - PR Newswire